Vor Biopharma Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
Item 15. Exhibits, Financial Statement Schedules.
(1)
For a list of the financial statements included herein, see Index to the Consolidated Financial Statements on page F-1 of this Annual Report on Form 10-K, incorporated into this Item by reference.
(2)
Schedules have been omitted since they are either not required or not applicable or the information is otherwise included herein.
(3)
Exhibits
| Incorporated by Reference | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit Number | Filing Date | Filed Herewith |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant | 8-K | 001-39979 | 3.1 | February 9, 2021 | |
| 3.2 | Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 001-39979 | 3.1 | May 23, 2025 | |
| 3.3 | Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant. | 8-K | 001-39979 | 3.1 | September 17, 2025 | |
| 3.4 | Amended and Restated Bylaws of the Registrant | 8-K | 001-39979 | 3.2 | February 9, 2021 | |
| 4.1 | Form of Common Stock Certificate of the Registrant | S-1/A | 333-252175 | 4.1 | February 1, 2021 | |
| 4.2 | Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated June 30, 2020 | S-1/A | 333-252175 | 4.2 | February 1, 2021 | |
| 4.3 | Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 | X | ||||
| 4.4 | Form of Common Stock Warrant | 8-K | 001-39979 | 4.1 | December 27, 2024 | |
| 4.5 | Form of Pre-Funded Warrant to Purchase Common Stock | 8-K | 001-39979 | 10.1 | June 26, 2025 | |
| 10.1† | License Agreement, dated as of June 25, 2025, by and between Remegen Co, Ltd. and the Registrant | 10-Q | 001-39979 | 10.9 | August 12, 2025 | |
| 10.2^ | Lease Agreement, dated August 5, 2025, by and between the Company and 500 Boylston & 222 Berkeley Owner (DE) LLC | 10-Q | 001-39979 | 10.10 | August 12, 2025 | |
| 10.3+ | 2015 Stock Incentive Plan and Forms of Option Grant Agreements, Exercise | S-1 | 333-252175 | 10.5 | January 15, 2021 | |
| Notices and Restricted Stock Agreement | ||||||
|---|---|---|---|---|---|---|
| 10.4+ | 2021 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement | S-1/A | 333-252175 | 10.6 | February 1, 2021 | |
| 10.5+ | Amended and Restated 2021 Equity Incentive Plan | 8-K | 001-39979 | 10.1 | August 27, 2025 | |
| 10.6+ | 2021 Employee Stock Purchase Plan | S-1/A | 333-252175 | 10.7 | February 1, 2021 | |
| 10.7+ | 2023 Inducement Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Notice of Exercise, RSU Award Grant Notice and Award Agreement (RSU Award) thereunder | S-8 | 333-274275 | 99.1 | August 30, 2023 | |
| 10.8+ | Form of Indemnification Agreement with Executive Officers and Directors | S-1 | 333-252175 | 10.8 | January 15, 2021 | |
| 10.9+ | Offer Letter, by and between the Registrant and Robert Ang, dated June 28, 2019 | S-1 | 333-252175 | 10.9 | January 15, 2021 | |
| 10.10+ | Transition Agreement, dated as of June 25, 2025, by and between the Registrant and Robert Ang | 8-K | 001-39979 | 10.6 | June 26, 2025 | |
| 10.11+ | Employment Agreement, dated as of June 25, 2025, by and between the Registrant and Jean-Paul Kress | 8-K | 001-39979 | 10.7 | June 26, 2025 | |
| 10.12+ | Employment Agreement, dated as of July 9, 2025, by and between the Registrant and Sandesh Mahatme | 8-K | 001-39979 | 10.1 | July 10, 2025 | |
| 10.13+ | Employment Agreement, dated as of July 17, 2025, by and between the Registrant and Qing Zuraw | 8-K | 001-39979 | 10.1 | July 22, 2025 | |
| 10.14+ | Amendment to Employment Agreement, dated November 2, 2025, by and between the Registrant and Qing Zuraw | 10-Q | 001-39979 | 10.6 | November 13, 2025 | |
| 10.15+ | Non-Employee Director Compensation Policy | X | ||||
| 10.16 | Sales Agreement, dated December 23, 2022, by and between the Registrant and Stifel, Nicolaus & Company, Incorporated | 8-K | 001-39979 | 1.1 | December 23, 2022 | |
| 10.17† | Form of Securities Purchase Agreement, dated June 25, 2025, by and between the Registrant and Yantai | 8-K | 001-39979 | 10.2 | June 26, 2025 | |
| Rongpu Investment Partnership (Limited Partnership) | ||||||
|---|---|---|---|---|---|---|
| 10.18 | Form of Securities Purchase Agreement, dated June 25, 2025, by and between the Registrant and the investors named therein | 8-K | 001-39979 | 10.3 | June 26, 2025 | |
| 10.19 | Form of Securities Purchase Agreement, dated December 15, 2025, by and between the Registrant and the investors named therein | 8-K | 001-39979 | 10.1 | December 18, 2025 | |
| 10.20 | Form of Registration Rights Agreement, dated June 25, 2025, by and between the Registrant and the investors named therein | 8-K | 001-39979 | 10.4 | June 26, 2025 | |
| 10.21 | Form of Registration Rights Agreement, dated December 15, 2025, by and between the Registrant and the investors named therein | 8-K | 001-39979 | 10.2 | December 18, 2025 | |
| 10.22 | Form of Support Agreement, dated June 25, 2025, by and between the Registrant and the investors named therein | 8-K | 001-39979 | 10.5 | June 26, 2025 | |
| 19.1 | Insider Trading and Window Period Policy | 10-K | 001-39979 | 19.1 | March 20, 2025 | |
| 21.1 | Subsidiaries of the Registrant | S-1 | 333-252175 | 21.1 | January 15, 2021 | |
| 23.1 | Consent of Ernst & Young LLP | X | ||||
| 31.1 | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 31.2 | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 32.1* | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | ||||
| 97.1 | Incentive Compensation Recoupment Policy | 10-K | 001-39979 | 97.1 | March 20, 2025 | |
| 101.INS | Inline XBRL Instance Document | X |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | X |
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | X |
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | X |
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | X |
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | X |
- Indicates management contract or compensatory plan.
† Portions of the exhibit have been omitted as the Registrant has determined that: (i) the omitted information is not material; and (ii) the omitted information is the type that the Registrant treats as private or confidential.
^ Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant will furnish a supplemental copy of any omitted schedule or similar attachment to the SEC upon request.
*This certification is being furnished and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and are not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.